Introduction {#S0001}
============

In 2012, the World Health Organization (WHO) estimated there were 1.3 million HIV-positive individuals in the United States and Canada and 1.5 million in the countries of Latin America (including Mexico) \[[@CIT0001]\]. In the United States, over 16% of individuals self-identified as Hispanic or Latino in the 2010 US census (defined as persons of Cuban, Mexican, Puerto Rican, South or Central American or other Spanish culture or origin regardless of race). Latinos in the United States have a rate of new HIV infections approximately three times greater than among non-Hispanic whites, but lower rates of engagement at all stages of the care continuum \[[@CIT0002]--[@CIT0004]\]. US Latinos are also more likely to be diagnosed with HIV at later disease stages, and disparities in obtaining medical care can be exacerbated by a lack of insurance, linguistic barriers, stigma and differences in patient-provider communication \[[@CIT0005]--[@CIT0008]\].

For HIV-positive Latinos in Mexico, Central America and South America, the availability of HIV care and antiretroviral therapy (ART) has expanded rapidly over the past decade, with approximately 75% of the estimated 790,000 persons in need of ART able to access treatment \[[@CIT0001]\]. Latin America has diverse economic and social contexts, and prior studies have found that mortality and programme retention vary considerably between countries \[[@CIT0009]--[@CIT0012]\]. A recent analysis of six Latin American countries and one Caribbean country found that the overall mortality rate after five years of ART, estimated to be 10%, was generally lower than that observed in sub-Saharan Africa, but higher than that in Europe and North America \[[@CIT0012]--[@CIT0016]\], although rates were heterogeneous between countries.

The goal of this study was to estimate regional differences in clinical characteristics at ART initiation, mortality, ART discontinuation or changes and virologic failure among HIV-positive Latinos in the Americas. We compared outcomes of HIV-positive Latino patients initiating ART in Canada and the United States (hereafter referred to as *North America*) to those in patients in six Latin American countries (Argentina, Brazil, Chile, Honduras, Mexico and Peru) using the regional databases of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) network.

Methods {#S0002}
=======

Participants and settings {#S0002-S20001}
-------------------------

Patient-level HIV treatment and care data were aggregated from two multinational regional consortia of IeDEA: the Caribbean, Central and South America Network for HIV research (CCASAnet) and the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). These consortia have been profiled elsewhere \[[@CIT0017],[@CIT0018]\].

Briefly, CCASAnet is a network of clinical sites in seven diverse Caribbean, Central and South American countries that pools data collected as part of HIV treatment and care programmes. In this study, we included data from eight CCASAnet sites in six countries: Hospital Fernández and Centro Médico Huésped in Buenos Aires, Argentina (HF/CMH-Argentina); Instituto Nacional de Infectologia Evandro Chagas in Rio de Janeiro, Brazil (INI-Brazil); Fundación Arriarán in Santiago, Chile (FA-Chile); Instituto Hondureño de Seguridad Social and Hospital de Especialidades in Tegucigalpa, Honduras (IHSS/HE-Honduras); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City, Mexico (INNSZ-Mexico); and Instituto de Medicina Tropical Alexander von Humboldt in Lima, Peru (IMTAvH-Peru). The CCASAnet site in Haiti was not included, given Haiti\'s African ethnic ancestry and non-Hispanic cultural heritage.

NA-ACCORD includes ≥200 sites in 25 single and multisite cohorts throughout the United States and Canada. In this study, data from 11 NA-ACCORD clinical cohorts were included: Fenway Community Health Center (Boston, MA), HIV Research Network, Johns Hopkins HIV Clinical Cohort (Baltimore, MD), Montreal Chest Institute Immunodeficiency Service Cohort, Ontario HIV Treatment Network Cohort Study, Retrovirus Research Center, Southern Alberta Clinic Cohort, Study of the Consequences of the Protease Inhibitor Era, University of Alabama at Birmingham 1917 Clinic Cohort, University of Washington HIV Cohort and Vanderbilt-Meharry Centers for AIDS Research (CFAR) Cohort. These sites included patients from 17 US states, Puerto Rico, and 4 Canadian provinces ([Figure 1](#F0001){ref-type="fig"}). Latinos in NA-ACCORD were identified based on either self-reported Hispanic ethnicity or self-reported country of birth in South America, Central America, Spanish-speaking countries in the Caribbean or Mexico. The NA-ACCORD cohorts not included in the analysis either did not have patients with Hispanic ethnicity or declined to provide data.

![Geographic distribution of NA-ACCORD and CCASAnet patients included in the analysis cohort.](JIAS-19-20684-g001){#F0001}

Our analysis cohort was restricted to ART-naive adult HIV-positive patients initiating ART between 2000 and 2011. Patients with an undetectable HIV-1 RNA viral load (VL) prior to reported date of ART initiation were excluded. Outcomes were assessed using data collected through 31 December 2011.

Clinical and epidemiological data were collected at each centre, de-identified and sent to the Data Coordinating Center at Vanderbilt University, USA. Institutional ethics review boards from all sites and Vanderbilt approved the project, waiving the requirement for individual patient informed consent.

Outcomes {#S0002-S20002}
--------

The time from ART initiation to each of five long-term outcomes was assessed: all-cause mortality, treatment interruption, major treatment change, virologic failure and loss to follow-up. ART was defined as a combination of three antiretroviral agents from at least two classes, or a triple nucleoside/nucleotide reverse transcriptase inhibitor regimen containing abacavir or tenofovir. Patients without an event were censored at 31 December 2011 or the date of their last clinical, pharmacy or laboratory visit, whichever occurred first.

Participant deaths in NA-ACCORD are recorded by the individual cohorts when the death can be confirmed, and deaths among patients lost to care are ascertained using routine surveillance and matching of US national and Canadian provincial death indexes. In CCASAnet, methods to ascertain death differ across sites. At IHSS/HE-Honduras, deaths are recorded after field workers contact patient family members following a missed visit. At all other sites, deaths occurring at affiliated hospitals or other clinical sites are recorded, as are notifications of deaths by relatives of patients. Additionally, study staff at INI-Brazil, FA-Chile, INNSZ-Mexico and IMTAvH-Peru sites query government death registry databases for patients lost to care at least annually.

Treatment interruption was defined as an interruption of the initial ART regimen for \>14 days. Major treatment change included switching to a "second-line" regimen, defined as (1) a change to a boosted protease inhibitor (PI)-based regimen; (2) switching to a different PI if a patient\'s first regimen included a boosted PI; (3) switching to a "third-line" drug (darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or raltegravir); or (4) changing to non-nucleoside reverse transcriptase inhibitor (NNRTI), boosted PI or switching, deleting or adding a third-line drug for those patients who had started treatment on a third-line drug. Virologic failure was defined as at least one of the following: (1) VL \>400 copies/mL after six months of therapy, (2) VL \<400 copies/mL followed by a single value \>1000 copies/mL or (3) VL \<400 copies/mL followed by two consecutive VL \>400 copies/mL. The threshold of 400 copies/mL was chosen based on the detection limit for assays used at many of the sites during the study period. Patients who did not have a VL measurement after ART initiation were excluded from the virologic failure analyses. Patients who had a gap between VL measurements of greater than one year were censored at the last measurement prior to the gap. Loss to follow-up (LFU) was defined as lack of information about the patient within 180 days prior to the database closing date; for patients lost to follow-up, the date of LFU was defined as date of their last visit.

Statistical analysis {#S0002-S20003}
--------------------

Univariate comparisons were performed using Wilcoxon rank sum and chi-square tests. Kaplan-Meier estimates and corresponding confidence intervals (CIs) of the probability of mortality were calculated for each consortium. The cumulative incidence and corresponding 95% CI of treatment interruption, ART regimen change and virologic failure were also estimated and these models accounted for mortality as a competing risk. Separate multivariable Cox proportional hazards models were fit to compare the hazard of death, major treatment modification and treatment failure between patients in CCASAnet and NA-ACCORD. All multivariable models were adjusted for age, sex, reported mode of transmission, nadir CD4+ T-cell count (CD4 count) and clinical AIDS prior to treatment initiation, initial ART regimen and year of ART initiation. Restricted cubic splines were used for continuous variables to account for non-linear trends \[[@CIT0019]\]. Multiple imputation was implemented to impute missing covariate values \[[@CIT0020]\].

Different frequencies of VL measurement between cohorts may have biased the results since patients with more VL measurements had more opportunities to be classified as a treatment failure. We thus compared the incidence of a detectable VL greater than six months after ART initiation while accounting for the number of VL measurements using a multivariable negative binomial regression model. We report the adjusted relative proportions of detectable VL per measurement and corresponding 95% CI.

Brazilian HIV treatment sites contributing data to CCASAnet were included in the primary analysis, as were Brazilian patients living in the United States or Canada and enrolled in NA-ACCORD (the US census definition of *Latino* includes Brazilians). However, the ethnic heritage of Brazil includes a large component of African migration, and we performed subregion analyses which excluded patients initiating ART in Brazil and patients born in Brazil initiating ART in North America. We also performed a subregion analysis comparing NA-ACCORD patients reporting Mexico as their country of origin with CCASAnet patients from Mexico.

All analyses were performed using R version 3.1.2; analysis code is available at [www.biostat.mc.vanderbilt.edu/ArchivedAnalyses](http://www.biostat.mc.vanderbilt.edu/ArchivedAnalyses).

Results {#S0003}
=======

From 2000 to 2011, a total of 11,186 ART-naive Latino patients initiated ART at one of 19 sites; 8400 (75%) at one of 8 CCASAnet sites in Latin America and 2786 (25%) in one of 11 NA-ACCORD cohorts with clinical sites in 17 US states and 4 Canadian provinces ([Figure 1](#F0001){ref-type="fig"}). CCASAnet patients included 2041 initiating ART in Argentina, 1792 in Brazil, 1347 in Chile, 882 in Honduras, 804 in Mexico and 1534 in Peru. Latinos initiating ART in North America included 294 with a known country of birth (156 from Mexico, 40 from other Central American countries, 69 from South American countries and 29 from the United States); the remaining 2492 patients self-reported as Latino.

Demographic and clinical characteristics of patients starting ART in each cohort are shown in [Table 1](#T0001){ref-type="table"}. Patients initiating ART in CCASAnet were significantly younger (median 35 vs. 37 years old), more likely to be female (27% vs. 20%) and less likely to have acquired HIV through injection drug use (2% vs. 12%) than Latinos initiating ART in NA-ACCORD (*p*\<0.001 for all). Median follow-up was 3.3 years (interquartile range (IQR): 1.2 to 6.0) for patients initiating ART in CCASAnet and 2.7 years (IQR: 1.0 to 5.6) for Latinos in NA-ACCORD.

###### 

Description of cohort participants at antiretroviral therapy initiation

                                    CCASAnet (*n=*8400)   NA-ACCORD (*n=*2786)   *p*
  --------------------------------- --------------------- ---------------------- ---------
  Age, years                        35 (29 to 43)         37 (30 to 44)          \<0.001
  Sex                                                                            \<0.001
   Female                           2268 (27.0%)          550 (19.7%)            
   Male                             6132 (73.0%)          2236 (80.3%)           
  Route of infection                                                             \<0.001
   Heterosexual                     3841 (45.7%)          1040 (37.3%)           
   MSM                              3248 (38.7%)          1313 (47.1%)           
   IDU                              179 (2.1%)            336 (12.0%)            
   Other                            63 (0.8%)             74 (2.7%)              
   Unknown                          1069 (12.7%)          23 (0.9%)              
  Clinical stage                                                                 \<0.001
   AIDS                             2443 (29.1%)          605 (21.7%)            
   Not AIDS                         4561 (54.3%)          1735 (62.3%)           
   Missing                          1396 (16.6%)          446 (16.0%)            
  Nadir CD4 count, cells/µL         148 (54 to 246)       195 (68 to 298)        \<0.001
   Missing                          980 (11.7%)           170 (6.1%)             
  Baseline CD4 count, cells/µL      150 (55 to 253)       212 (79 to 323)        \<0.001
   Missing                          1422 (16.9%)          248 (9%)               
  Baseline viral load (log~10~)     5.0 (4.5 to 5.4)      4.8 (4.2 to 5.3)       \<0.001
   Missing                          2708 (32.2%)          345 (12.4%)            
  Initial regimen                                                                \<0.001
   NNRTI                            6699 (79.8%)          1240 (44.5%)           
   Boosted PI                       1183 (14.1%)          974 (35.0%)            
   Other                            518 (6.2%)            572 (20.5%)            
  Nucleoside backbone                                                            \<0.001
   ZDV+3TC                          5604 (66.7%)          597 (21.4%)            
   TDF+FTC                          640 (7.6%)            1564 (56.1%)           
   TDF+3TC                          562 (6.7%)            127 (4.6%)             
   D4T+3TC                          873 (10.4%)           123 (4.4%)             
   ABC+3TC                          331 (3.9%)            183 (6.6%)             
   Other                            390 (4.6%)            192 (6.9%)             
  Regimen anchor                                                                 \<0.001
   EFV                              5470 (65.1%)          1145 (41.1%)           
   NVP                              1211 (14.4%)          83 (3.0%)              
   NFV                              78 (0.9%)             454 (16.3%)            
   LPV+ritonavir                    419 (5.0%)            316 (11.3%)            
   ATV+ritonavir                    279 (3.3%)            454 (16.3%)            
   Other                            943 (11.2%)           517 (18.6%)            
  Initiation year                   2007 (2004 to 2009)   2007 (2003 to 2009)    \<0.001
  VL measurements per person-year   1.95 (1.13 to 2.82)   3.38 (2.50 to 4.41)    \<0.001
  At least one VL measurement                                                    \<0.001
   Yes                              7522 (89.5%)          2683 (96.3%)           
   No                               878 (10.5%)           103 (3.7%)             

CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection drug use; MSM, men who have sex with men; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; VL, viral load. Antiretroviral agents: 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ATV, atazanavir; D4T, stavudine; EFV, efavirenz; LPV, lopinavir; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine.

Crude mortality rates were 2.1 and 1.4 per 100 person-years for ART initiators in CCASAnet and NA-ACCORD, respectively. All-cause mortality early after ART initiation was higher in CCASAnet: 4.4% (95% CI: 4.0 to 4.9%) died during the first year in CCASAnet compared with 1.5% (95% CI: 1.0% to 2.0%) in NA-ACCORD ([Figure 2](#F0002){ref-type="fig"}). After one year, the crude mortality rates were 1.28 and 1.33 per 100 person-years for ART initiators who survived the first year in CCASAnet and NA-ACCORD, respectively.

![Cumulative mortality among Latino patients initiating ART at Latin American (CCASAnet) and North American (NA-ACCORD) sites. Time zero represents start of first antiretroviral therapy regimen. Solid lines indicate 95% confidence intervals around estimated incidence of mortality.](JIAS-19-20684-g002){#F0002}

In multivariable Cox analyses, CCASAnet patients had a higher hazard of mortality after ART initiation (adjusted hazard ratio (AHR) 1.61; 95% CI: 1.32 to 1.96), adjusting for age, sex, CD4 count, year of ART initiation, intravenous drug use, prior AIDS diagnosis and ART regimen ([Table 2](#T0002){ref-type="table"}). Among patients who died in the first year, there was no significant difference in CD4 count at ART initiation between CCASAnet and NA-ACCORD (50 vs. 36 cells/µL, *p*=0.35), though CCASAnet patients were younger (37 vs. 42 years, *p*=0.02) and less likely to have an AIDS diagnosis before ART initiation (44% vs. 58%, *p*=0.04; Supplementary Table 1).

###### 

Comparison of all-cause mortality, treatment interruption, regimen change and virologic failure between Latinos initiating antiretroviral therapy in NA-ACCORD and CCASAnet

                                 Death hazard ratio    Treatment interruption hazard ratio   Second-line regimen switch hazard ratio   Virologic failure hazard ratio
  ------------------------------ --------------------- ------------------------------------- ----------------------------------------- --------------------------------
  Cohort                                                                                                                               
   NA-ACCORD                     Ref                   Ref                                   Ref                                       Ref
   CCASAnet                      1.61 (1.32 to 1.96)   0.46 (0.42 to 0.50)                   0.56 (0.51 to 0.62)                       0.52 (0.48 to 0.57)
  Sex                                                                                                                                  
   Female                        Ref                   Ref                                   Ref                                       Ref
   Male                          1.02 (0.87 to 1.20)   0.75 (0.68 to 0.82)                   0.76 (0.69 to 0.82)                       0.75 (0.68 to 0.82)
  Age                                                                                                                                  
   20                            0.73 (0.52 to 1.04)   1.47 (1.26 to 1.73)                   1.25 (1.06 to 1.47)                       1.53(1.30 to 1.80)
   30                            0.82 (0.71 to 0.95)   1.22 (1.12 to 1.34)                   1.09 (1.00 to 1.20)                       1.04 (0.95 to 1.14)
   40                            Ref                   Ref                                   Ref                                       Ref
   50                            1.31 (1.20 to 1.43)   0.82 (0.76 to 0.88)                   0.98 (0.92 to 1.04)                       0.93 (0.87 to 0.99)
   60                            1.77 (1.42 to 2.20)   0.68 (0.55 to 0.83)                   0.99 (0.83 to 1.17)                       0.78 (0.65 to 0.94)
  Clinical AIDS at baseline                                                                                                            
   No                            Ref                   Ref                                   Ref                                       Ref
   Yes                           1.27 (1.07 to 1.49)   1.05 (0.94 to 1.17)                   1.04 (0.94 to 1.15)                       0.94 (0.85 to 1.05)
  Baseline CD4 count, cells/µL                                                                                                         
   50                            2.28 (1.80 to 2.88)   0.88 (0.78 to 0.99)                   1.32 (1.17 to 1.49)                       1.05 (0.93 to 1.18)
   100                           1.68 (1.34 to 2.10)   0.85 (0.76 to 0.95)                   1.22 (1.08 to 1.36)                       1.00 (0.90 to 1.13)
   200                           1.09 (0.93 to 1.28)   0.90 (0.84 to 0.95)                   1.05 (0.98 to 1.13)                       0.90 (0.85 to 0.97)
   350                           Ref                   Ref                                                                             Ref
  Initiation year                                                                                                                      
   2000                          0.82 (0.62 to 1.09)   1.33 (1.16 to 1.54)                   0.86 (0.74 to 1.01)                       1.88 (1.62 to 2.18)
   2002                          0.92 (0.79 to 1.07)   1.25 (1.15 to 1.35)                   0.86 (0.79 to 0.94)                       1.56 (1.44 to 1.70)
   2004                          1.00 (0.90 to 1.11)   1.15 (1.08 to 1.22)                   0.89 (0.84 to 0.94)                       1.27 (1.20 to 1.36)
   2006                          Ref                   Ref                                   Ref                                       Ref
   2008                          0.97 (0.85 to 1.10)   0.85 (0.79 to 0.91)                   1.29 (1.20 to 1.38)                       0.85 (0.79 to 0.92)
   2010                          1.02 (0.82 to 1.27)   0.74 (0.65 to 0.84)                   1.93 (1.71 to 2.17)                       0.95 (0.83 to 1.10)
  ART regimen class                                                                                                                    
   NNRTI                         Ref                   Ref                                   Ref                                       Ref
   PI                            0.93 (0.77 to 1.13)   1.18 (1.06 to 1.31)                   1.05 (0.95 to 1.17)                       1.38 (1.24 to 1.53)
   Other                         1.27 (1.00 to 1.60)   1.50 (1.34 to 1.69)                   1.73 (1.53 to 1.94)                       1.70 (1.50 to 1.91)
  History of IDU                                                                                                                       
   No                            Ref                   Ref                                   Ref                                       Ref
   Yes                           1.64 (1.21 to 2.21)   1.42 (1.22 to 1.65)                   1.28 (1.08 to 1.51)                       1.71 (1.46 to 2.01)

Estimates presented as hazard ratio (95% confidence interval). CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection drug use; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase inhibitor; Ref, reference category; PI, protease inhibitor. Continuous variables were modelled using restricted cubic splines, and the hazard ratios and confidence intervals shown for age, baseline CD4 count, and year of ART initiation represent predicted values estimated from the model.

The cumulative incidence of an ART treatment interruption, major treatment change, virologic failure and LFU were lower for CCASAnet participants ([Figure 3](#F0003){ref-type="fig"}). The cumulative incidence of an ART treatment interruption ≥14 days was lower in CCASAnet compared to NA-ACCORD at one year (0.10 vs. 0.21) and five years (0.21 vs. 0.46). After controlling for characteristics at ART initiation, the hazard ratio for treatment interruption was significantly lower for patients in CCASAnet (AHR: 0.46; 95% CI: 0.42 to 0.50; [Table 2](#T0002){ref-type="table"}).

![Cumulative incidence of antiretroviral therapy (ART) treatment interruption, ART regimen change, virologic failure and loss to follow-up among CCASAnet and Latino NA-ACCORD patients. All panels show the cumulative incidence of each outcome among CCASAnet and NA-ACCORD patients using a competing risks model where time zero represents the start of the first ART regimen. Solid lines indicate 95% confidence intervals around estimated incidence of treatment interruption. (a) Cumulative incidence of a 14-day or greater ART treatment interruption; (b) cumulative incidence of a change from the initial treatment to a second-line regimen; (c) cumulative incidence of virologic failure among patients who had at least one viral load measurement after treatment initiation; (d) cumulative incidence of loss to follow-up.](JIAS-19-20684-g003){#F0003}

One and five years after ART initiation, the cumulative incidence of a regimen change among patients initiating ART in CCASAnet was 0.07 and 0.23, respectively, and among Latinos initiating ART in NA-ACCORD, 0.13 and 0.39 ([Figure 3](#F0003){ref-type="fig"}b). Similarly, the hazard ratio for changing the initial regimen was significantly lower for patients in CCASAnet (AHR: 0.56; 95% CI: 0.51 to 0.62; [Table 2](#T0002){ref-type="table"}). In CCASAnet, 70% changed from an NNRTI to boosted PI, 24% from one PI to another PI and 2% to a third-line drug. In NA-ACCORD, 41% changed from an NNRTI to a boosted PI, 36% from one PI to another PI and 21% changed to a regimen containing a third-line drug.

Patients initiating ART in CCASAnet also had a lower cumulative incidence of virologic failure (AHR 0.52, 95% CI: 0.48 to 0.57; [Table 2](#T0002){ref-type="table"} and [Figure 3](#F0003){ref-type="fig"}c). The results for virologic failure were not appreciably different when patients were censored at the start of a treatment interruption ≥14 days; the risk of virologic failure remained lower among CCASAnet patients (AHR 0.51, 95% CI: 0.45 to 0.56; data not shown). However, plasma VL was measured less frequently for patients in CCASAnet (median of 1.95 measurements per person per year vs. 3.38 among Latinos in NA-ACCORD). Nonetheless, the percentage of VL measurements after six months that were detectable remained lower for patients in CCASAnet (9.6%; 6157/64,043) than for Latinos in NA-ACCORD (19.7%; 6400/32,423; adjusted relative proportions of 0.53; 95%CI: 0.48 to 0.58).

Lastly, patients initiating ART in CCASAnet had a lower cumulative incidence of LFU than patients initiating ART in NA-ACCORD ([Figure 3](#F0003){ref-type="fig"}d). One and five years after ART initiation, the cumulative incidence of LFU among patients initiating ART in CCASAnet was 0.04 and 0.20, respectively, and higher among Latinos initiating ART in NA-ACCORD, 0.12 and 0.36.

Subregion analyses {#S0003-S20001}
------------------

Brazilian CCASAnet sites and Brazilian patients enrolled in NA-ACCORD were included in the primary analyses, but given the large component of African migration to Brazil we performed subregion analyses (Supplementary Table 2) that excluded patients initiating ART in Brazil (*n*=1792) and patients born in Brazil initiating ART in North America (*n*=2). The hazard ratio of death in CCASAnet compared to NA-ACCORD was lower when Brazilians were excluded (AHR: 1.27; 95% CI: 1.03 to 1.57), whereas there was little difference in the hazard ratios of treatment interruption, regimen change or virologic failure. Similarly, the percentage of VL measurements that were detectable after six months remained lower for patients initiating ART in CCASAnet in analyses excluding Brazil (adjusted relative proportion=0.52; 95% CI: 0.47 to 0.58).

Among the 804 patients initiating ART in Mexico and 156 Mexicans initiating ART in the United States or Canada, there was insufficient evidence to suggest a difference in mortality (AHR: 1.29; 95% CI: 0.43 to 3.85), although the hazard ratio was in the same direction as primary analyses. Patients initiating ART in Mexico had a lower hazard for virologic failure (AHR: 0.45; 95% CI: 0.33 to 0.63), although again this may have been driven by differences in the frequency of measurements. The percentage of detectable VL measurements was lower among patients initiating ART in Mexico (adjusted relative proportion=0.70; 95% CI: 0.43 to 1.15) but this difference was not statistically significant.

Discussion {#S0004}
==========

Latinos in the United States and Canada started ART with less severe immunosuppression and had greater survival, particularly in the first 12 months of care, as compared with individuals starting ART in Latin America, but Latinos in North America also appear to be at greater risk for treatment interruptions, treatment regimen changes, virologic failure and LFU.

The lower risk of mortality observed among Latinos in North America compared to those living in Latin America was most pronounced in the early years of ART. Early mortality in resource-limited settings has been well documented, and our results are largely consistent with other comparisons between resource-limited settings (primarily sub-Saharan Africa) and North America and Europe \[[@CIT0021]\]. Patients initiating ART in Latin America had a greater degree of immunosuppression. Although cause of death was not available, other studies have reported AIDS-related conditions as the leading cause of early mortality after treatment initiation in Latin America, and this predominance has not changed despite the improved survival observed in the era of modern combination ART regimens \[[@CIT0022]--[@CIT0025]\].

Compared to non-Hispanic whites, Latinos in the United States as a group are diagnosed at a more advanced HIV disease, and foreign-born, non-English speaking and male Latinos are at particularly high risk of delayed diagnosis \[[@CIT0026]--[@CIT0032]\]. Barriers to engagement in HIV care in the United States may be greater for Latinos than other ethnic groups. An analysis of 2010 data found that among Hispanics or Latinos diagnosed with HIV, rates at all stages of the care continuum were lower than among non-Hispanic whites \[[@CIT0003]\]. A recent study of a predominantly Hispanic HIV cohort in Texas, found that 46% of patients lacked insurance and an additional 14% were receiving Medicaid \[[@CIT0005]\]. There can also be particular challenges for Latinos due to linguistic barriers and differences in patient-provider communication. For example, prior studies have identified less patient-centred and psychosocial language use by HIV clinicians treating Hispanics versus non-Hispanics \[[@CIT0006]--[@CIT0008]\].

Prior studies have also identified important differences among native and foreign-born Latinos in the United States, which may be representative of broader geographic trends. Studies from the United States found that foreign-born Latino males are more likely to have acquired HIV through heterosexual contact as compared to US-born Latinos. Among HIV-positive Latinas, foreign-born women were older at first sexual contact, had fewer episodes of non-HIV sexually transmitted diseases and lower rates of drug and alcohol abuse \[[@CIT0027],[@CIT0033],[@CIT0034]\].

We examined health outcomes at CCASAnet sites in aggregate, but prior studies have found that mortality and programme retention vary considerably between countries in Latin America, which likely reflects differences in the underlying demographics of the HIV epidemic in the region, as well as local social and economic characteristics \[[@CIT0009],[@CIT0011]--[@CIT0013],[@CIT0035],[@CIT0036]\]. Heterogeneity in mortality could be related to different programme retention and death ascertainment. Rates of treatment change also vary by CCASAnet sites, with geographic differences in specific toxicities as well as uneven availability of second- and third-line medications, which may be a source of possible confounding \[[@CIT0037],[@CIT0038]\]. The cumulative incidence of regimen change in NA-ACCORD was higher than in CCASAnet, and 21% of patients changing regimens switched to a third-line agent in NA-ACCORD, compared to 2% in CCASAnet. This figure may reflect a greater availability of third-line agents driving a higher cumulative incidence of regimen change, particularly if the change occurs for tolerability issues (which might not be an option in CCASAnet countries with a more limited ART selection). However, it should be noted that cumulative incidence of virologic failure was also higher in NA-ACCORD, so the greater utilization of third-line agents may simply reflect a greater burden of HIV drug resistance.

A strength of this study was the large number of subjects contributing data from multiple countries. However, the largest number of North American Latino patients with known foreign birth location had migrated from Mexico, whereas the majority of CCASAnet patients were located in South America. Limitations of our data included the proportion of patients with no reported country of birth in NA-ACCORD. Other limitations included the lack of information on causes of death and potential confounding of the treatment interruption analysis related to how accurately sites record gaps in ART use (i.e. adherence) versus gaps in prescriptions for ART. Although we assessed time to virologic failure, we did not assess the role of adherence and viral resistance in treatment failure, nor toxicity or other reasons for ART change.

Conclusions {#S0005}
===========

Mortality rates were higher in Latin America, possibly due to treatment initiation at more advanced stages of HIV disease, whereas treatment interruption, major regimen modification, virologic failure and LFU were higher in North America, where barriers to receiving quality HIV care may be higher for Latino populations. These results emphasize once again the need for early diagnosis and treatment initiation in Latin America and reinforce the key role of ensuring US Latino HIV patients have consistent access to care to improve treatment outcomes.
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###### Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America
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